Immunome Inc
IMNM8.680USD
-0.240-2.69%
Close 06/25, 16:00（ET）Quotes delayed by 15 min
754.78MMarket Cap
LossP/E TTM
More Details of Immunome Inc Company
Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.
Company Info
Ticker SymbolIMNM
Company nameImmunome Inc
IPO dateOct 02, 2020
Founded at2015
CEODr. Clay B. Siegall, Ph.D.
Number of employees118
Security typeOrdinary Share
Fiscal year-endOct 02
Address18702 N. Creek Parkway
CityBOTHELL
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code98011
Phone16103213700
Websitehttps://immunome.com/
Ticker SymbolIMNM
IPO dateOct 02, 2020
Founded at2015
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
806.74K
+20.47%
Mr. Philip R. Wagenheim
Mr. Philip R. Wagenheim
Director
Director
406.15K
+3.44%
Mr. Isaac Barchas, J.D.
Mr. Isaac Barchas, J.D.
Lead Independent Director
Lead Independent Director
92.21K
-24.22%
Mr. Max Rosett
Mr. Max Rosett
Chief Financial Officer
Chief Financial Officer
47.48K
+139.10%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
36.41K
+15.92%
Dr. Jack Higgins, Ph.D.
Dr. Jack Higgins, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
18.73K
+38.44%
Ms. Sandra G. Stoneman
Ms. Sandra G. Stoneman
Chief Legal Officer, General Counsel, Corporate Secretary
Chief Legal Officer, General Counsel, Corporate Secretary
--
--
Dr. Phil Tsai
Dr. Phil Tsai
Chief Technical Officer
Chief Technical Officer
--
--
Dr. Sandra M Swain, M.D.
Dr. Sandra M Swain, M.D.
Independent Director
Independent Director
--
--
Dr. Bob Lechleider, M.D.
Dr. Bob Lechleider, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
806.74K
+20.47%
Mr. Philip R. Wagenheim
Mr. Philip R. Wagenheim
Director
Director
406.15K
+3.44%
Mr. Isaac Barchas, J.D.
Mr. Isaac Barchas, J.D.
Lead Independent Director
Lead Independent Director
92.21K
-24.22%
Mr. Max Rosett
Mr. Max Rosett
Chief Financial Officer
Chief Financial Officer
47.48K
+139.10%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
36.41K
+15.92%
Dr. Jack Higgins, Ph.D.
Dr. Jack Higgins, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
18.73K
+38.44%
Revenue Breakdown
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
No Data
By RegionUSD
Name
Revenue
Proportion
United States
9.04M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
T. Rowe Price Investment Management, Inc.
8.68%
Redmile Group, LLC
6.16%
BlackRock Institutional Trust Company, N.A.
5.87%
Enavate Sciences GP, LLC
5.48%
Point72 Asset Management, L.P.
5.01%
Other
68.79%
Shareholders
Shareholders
Proportion
T. Rowe Price Investment Management, Inc.
8.68%
Redmile Group, LLC
6.16%
BlackRock Institutional Trust Company, N.A.
5.87%
Enavate Sciences GP, LLC
5.48%
Point72 Asset Management, L.P.
5.01%
Other
68.79%
Shareholder Types
Shareholders
Proportion
Investment Advisor
33.48%
Investment Advisor/Hedge Fund
29.43%
Hedge Fund
14.85%
Corporation
8.26%
Research Firm
4.28%
Individual Investor
3.23%
Venture Capital
0.91%
Bank and Trust
0.29%
Pension Fund
0.14%
Other
5.14%
Institutional Shareholding
Updated: Mon, Mar 3
Updated: Mon, Mar 3
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
295
69.73M
91.15%
+848.96K
2024Q4
278
64.18M
84.45%
+3.64M
2024Q3
252
62.39M
103.49%
+7.38M
2024Q2
228
58.25M
97.90%
+16.13M
2024Q1
182
46.83M
84.41%
+22.74M
2023Q4
113
32.29M
78.79%
+19.76M
2023Q3
82
6.26M
40.47%
+930.23K
2023Q2
81
5.83M
36.98%
+582.43K
2023Q1
95
4.18M
34.54%
-644.30K
2022Q4
98
4.36M
36.09%
-940.25K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
T. Rowe Price Investment Management, Inc.
5.50M
6.33%
-262.06K
-4.55%
Dec 31, 2024
Redmile Group, LLC
4.83M
5.55%
-61.53K
-1.26%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
3.74M
4.3%
+134.54K
+3.73%
Dec 31, 2024
Enavate Sciences GP, LLC
3.48M
4%
+3.48M
--
Dec 31, 2024
The Vanguard Group, Inc.
3.00M
3.45%
-128.13K
-4.10%
Dec 31, 2024
EcoR1 Capital, LLC
3.88M
4.46%
--
--
Dec 31, 2024
Fidelity Management & Research Company LLC
3.92M
4.51%
-305.48K
-7.23%
Dec 31, 2024
Opaleye Management Inc.
2.04M
2.35%
+802.50K
+64.85%
Dec 31, 2024
View more
Related ETFs
Updated: Fri, Jun 6
Updated: Fri, Jun 6
Name
Proportion
WisdomTree BioRevolution Fund
0.97%
iShares Genomics Immunology and Healthcare ETF
0.71%
ALPS Medical Breakthroughs ETF
0.63%
Virtus LifeSci Biotech Clinical Trials ETF
0.5%
Main Thematic Innovation ETF
0.5%
SPDR S&P Biotech ETF
0.2%
iShares Micro-Cap ETF
0.15%
Direxion Daily S&P Biotech Bull 3X Shares
0.13%
Nuveen ESG Small-Cap ETF
0.06%
iShares ESG Aware MSCI USA Small-Cap ETF
0.05%
View more
WisdomTree BioRevolution Fund
Proportion0.97%
iShares Genomics Immunology and Healthcare ETF
Proportion0.71%
ALPS Medical Breakthroughs ETF
Proportion0.63%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.5%
Main Thematic Innovation ETF
Proportion0.5%
SPDR S&P Biotech ETF
Proportion0.2%
iShares Micro-Cap ETF
Proportion0.15%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.13%
Nuveen ESG Small-Cap ETF
Proportion0.06%
iShares ESG Aware MSCI USA Small-Cap ETF
Proportion0.05%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
